Imagine a virus so rapidly expanding that global cases have skyrocketed eight-fold in just two decades, making dengue fever one of the world's most pressing mosquito-borne threats today.
Key Takeaways
- In 2019, approximately 400 million dengue infections occurred worldwide, with about 96 million manifesting clinically with any severity
- Dengue causes an estimated 40,000 deaths annually globally, primarily due to severe dengue
- Between 2000 and 2019, dengue cases increased over 8-fold globally, reaching 5.2 million reported cases in 2019
- Brazil reported 6.2 million suspected cases in 2023-2024 season
- India had 250,000 dengue cases in 2023, with 200+ deaths
- Americas region saw 3.5 million cases in 2024 up to week 30
- Dengue fever is caused by four distinct serotypes: DENV-1, DENV-2, DENV-3, DENV-4
- Severe dengue, also known as dengue hemorrhagic fever (DHF), is characterized by plasma leakage leading to shock
- Incubation period for dengue is 4-10 days, averaging 5-7 days
- Dengue transmitted primarily by Aedes aegypti mosquito, also Aedes albopictus
- Aedes mosquitoes bite during daytime, peaking morning/evening
- Female Aedes aegypti lay 100-200 eggs per batch, up to 5 batches lifetime
- No specific antiviral treatment; supportive care reduces CFR from 20% to <1%
- WHO-recommended fluid management: isotonic IV fluids at 5-7 ml/kg/h in DSS
- Dengvaxia vaccine efficacy 60.8% against virologically confirmed dengue in seropositive
Dengue fever is a rapidly spreading global threat affecting billions and causing severe illness.
Clinical Aspects
1Dengue fever is caused by four distinct serotypes: DENV-1, DENV-2, DENV-3, DENV-4
Verified2Severe dengue, also known as dengue hemorrhagic fever (DHF), is characterized by plasma leakage leading to shock
Verified3Incubation period for dengue is 4-10 days, averaging 5-7 days
Verified4Classic symptoms include high fever (40°C/104°F), severe headache, retro-orbital pain, myalgia, arthralgia
Directional5Warning signs of severe dengue appear 24–48 hours after fever subsides: abdominal pain, persistent vomiting, bleeding
Single source6Thrombocytopenia (<100,000/mm³) is common, with platelets often <50,000 in severe cases
Verified7Hematocrit rise >20% indicates plasma leakage in dengue shock syndrome (DSS)
Verified8NS1 antigen detectable 1st day post-onset, up to 9 days, used for early diagnosis
Verified9IgM antibodies appear after 5 days, IgG after 14 days, indicating past/current infection
Directional10Severe dengue classified by WHO 2009 criteria: plasma leakage, severe bleeding, organ impairment
Single source11Children under 5 years have higher risk of DSS, with mortality up to 20% if untreated
Verified12Secondary infection with heterologous serotype increases severe dengue risk 15-80 fold
Verified13Rash in dengue: macular or maculopapular, appears day 3-4 in 50-80% cases
Verified14Liver involvement: ALT/AST elevated in 30-50%, severe hepatitis in <1%
Directional15Neurological manifestations in 0.5-21%: encephalitis, meningitis, Guillain-Barré
Single source16Myocarditis rare, but ECG changes in 10-15% hospitalized patients
Verified17Critical phase: days 3-7, when defervescence occurs and plasma leakage peaks
Verified18Recovery phase: reabsorption of leaked plasma, takes 2-3 days
Verified19Atypical manifestations: acute kidney injury in 2-5% severe cases
Directional20PCR detects viral RNA from day 0-5, gold standard for serotyping
Single sourceClinical Aspects Interpretation
Dengue fever, a master of four-faced deception, tricks your immune system into a friendly fire that can suddenly escalate from a miserable flu-like week into a critical emergency, especially if it recognizes you from a past encounter.
Control Measures
1No specific antiviral treatment; supportive care reduces CFR from 20% to <1%
Verified2WHO-recommended fluid management: isotonic IV fluids at 5-7 ml/kg/h in DSS
Verified3Dengvaxia vaccine efficacy 60.8% against virologically confirmed dengue in seropositive
Verified4Qdenga vaccine 80% effective against hospitalization in 4-59 year olds
Directional5Insecticide space spraying reduces vectors by 50-80% short-term
Single source6Larviciding with temephos effective up to 3 months in containers
Verified7Community source reduction eliminates 70-90% breeding sites
Verified8Wolbachia replacement suppresses dengue by 77% for 3+ years
Verified9Integrated Vector Management (IVM) recommended, combining chemical/biological/physical
Directional10Personal protection: DEET 20-50% repels Aedes for 4-8 hours
Single source11Case management training reduced CFR to 0.13% in SE Asia
Verified12Mass screening in outbreaks detects severe cases early, preventing 50% deaths
Verified13Sterile Insect Technique (SIT) reduces Aedes by 80% in trials
Verified14Dengue vaccines contraindicated in seronegative children for CYD-TDV
Directional15Household insecticide spraying kills 90% resting mosquitoes indoors
Single source16Climate-based early warning systems predict outbreaks 1-3 months ahead
Verified17Bacillus thuringiensis israelensis (Bti) larvicide safe, 95% effective 7 days
Verified18School-based education campaigns increase prevention by 40%
VerifiedControl Measures Interpretation
While no magic bullet exists, the collective arsenal—from vigilant case management slashing fatality rates to community action clearing breeding grounds and Wolbachia's clever mosquito makeover—proves we can outflank dengue by combining our best tools with relentless consistency.
Global Burden
1In 2019, approximately 400 million dengue infections occurred worldwide, with about 96 million manifesting clinically with any severity
Verified2Dengue causes an estimated 40,000 deaths annually globally, primarily due to severe dengue
Verified3Between 2000 and 2019, dengue cases increased over 8-fold globally, reaching 5.2 million reported cases in 2019
Verified4Up to 4 billion people are at risk of dengue infection worldwide, living in dengue-endemic areas
Directional5In 2023, over 6.5 million dengue cases were reported in 86 countries across all WHO regions
Single source6The global incidence of dengue has risen 30-fold in the past 50 years
Verified7Dengue is endemic in more than 100 countries in Asia, Africa, and the Americas
Verified8An estimated 390 million dengue infections occur annually, mostly asymptomatic
Verified9Severe dengue accounts for about 500,000 hospitalizations and 20,000 deaths yearly
Directional10From 2010-2020, dengue notifications increased by 175% globally
Single source11In 2022, the Americas reported over 3.3 million dengue cases
Verified12Southeast Asia contributes about 70% of the global dengue burden
Verified13Africa's dengue burden is underreported, with only 1% of global cases officially recorded despite high risk
Verified14The Western Pacific Region reported 2.7 million cases in 2023
Directional15Global dengue mortality rate is around 0.5-1% in hospitalized severe cases
Single source16In 2015-2020, hyperendemic countries reported average annual incidence of 300-500 cases per 100,000 population
Verified17Dengue vaccine CYD-TDV prevented 80.8% of severe dengue in children aged 9+ with prior exposure
Verified18Economic cost of dengue globally exceeds $8.9 billion annually
Verified19In 2024, preliminary data shows over 10 million suspected cases worldwide
Directional20Dengue case-fatality ratio (CFR) in Asia is 0.74%, higher in children under 5
Single source21In 2023, Bangladesh reported 321,000 cases and 271 deaths
Verified22Thailand sees 100,000-200,000 cases yearly, with CFR 0.1-0.3%
Verified23Philippines had 258,000 cases in 2023, highest in decades
Verified24Vietnam reported 150,000 cases in early 2023
Directional25Global dengue DALYs lost are estimated at 2.2 million annually
Single source26In 2019, Americas had 5.2 million cases, 53,000 severe
Verified27Africa's estimated 20 million annual infections vs. <50,000 reported
Verified28Europe reports imported cases: 20,000+ in 2018-2022
Verified29Dengue hyperendemicity affects 3.9 billion people in 129 countries
Directional302023 global severe dengue cases exceeded 1 million
Single sourceGlobal Burden Interpretation
Dengue fever, once a tropical nuisance, has in half a century swelled into a global epidemic, stealthily infecting nearly 400 million annually, menacing half the world’s population with a bite that now claims tens of thousands of lives each year and shows no sign of relenting.
Regional Distribution
1Brazil reported 6.2 million suspected cases in 2023-2024 season
Verified2India had 250,000 dengue cases in 2023, with 200+ deaths
Verified3Americas region saw 3.5 million cases in 2024 up to week 30
Verified4Southeast Asia reported 1.8 million cases in 2023
Directional5Argentina had 137,000 cases in 2023-2024
Single source6Mexico reported 35,000 cases and 66 deaths in 2023
Verified7Indonesia sees 100,000+ cases annually, with peaks up to 200,000
Verified8Colombia had 129,000 cases in 2023
Verified9Peru reported 200,000+ cases in 2023-2024
Directional10Sri Lanka had 30,000 cases in 2023
Single source11Paraguay saw 231,000 cases in 2023-2024, highest ever
Verified12Bangladesh epidemic in 2023: 400,000 suspected cases
Verified13Americas CFR for severe dengue is 0.06% in 2023
Verified14Western Pacific islands like Fiji report incidence >1000/100,000 population
Directional15Central America: Nicaragua 50,000 cases in 2023
Single source16Southern Cone countries: 70% of Americas cases in 2023-2024
Verified17India’s Delhi reported 10,000 cases in 2023 monsoon
Verified18Maldives had outbreak with 1,500 cases in 2023
Verified19Africa: Reunion Island 50,000 cases in 2024
Directional20Caribbean: Puerto Rico 1,500 local cases in 2023
Single source21Southeast Asia urban areas have 2-3x higher incidence than rural
Verified22Brazil’s Sao Paulo state: 300,000 cases in 2023-2024
Verified23Thailand’s Bangkok incidence 200/100,000 yearly
VerifiedRegional Distribution Interpretation
This alarmingly global guest list, with millions checked in from Brazil to Bangkok, suggests the dengue virus has not only skipped the RSVP but is currently throwing a rave in our collective backyard, and we're desperately short on bouncers.
Vector Biology
1Dengue transmitted primarily by Aedes aegypti mosquito, also Aedes albopictus
Verified2Aedes mosquitoes bite during daytime, peaking morning/evening
Verified3Female Aedes aegypti lay 100-200 eggs per batch, up to 5 batches lifetime
Verified4Extrinsic incubation period in mosquito: 8-12 days at 25-30°C
Directional5Aedes aegypti prefers urban breeding in artificial containers: tires, drums, pots
Single source6Aedes albopictus more adaptable, breeds in tree holes, leaf axils in rural/periurban
Verified7Mosquito vector density threshold for outbreaks: 1 female per 10 houses
Verified8Vertical transmission of DENV in eggs occurs at low rate (5-20%)
Verified9Aedes aegypti flight range limited to 100-300 meters from breeding sites
Directional10Optimal breeding temperature 25-30°C, humidity >60%
Single source11Aedes lifespan 2-4 weeks, females need blood meal for egg development
Verified12Wolbachia-infected Aedes reduce dengue transmission by 77% in trials
Verified13Larval indices: House Index >1%, Container Index >5% indicate high risk
Verified14Aedes aegypti absent below 10°C, thrives up to 37°C
Directional15Transovarial infection rates up to 30% in field Aedes populations
Single source16Aedes albopictus expanding to temperate regions due to tire trade
Verified17Breeding sites produce 80% of vectors: small water collections <1L
Verified18Vector competence: DENV-2 most efficiently transmitted by Aedes
Verified19Pyrethroid resistance in 70% Aedes populations globally
Directional20Aedes aegypti anthropophilic, rarely bites animals
Single sourceVector Biology Interpretation
Dengue's success is a monument to our own carelessness, as it thrives in the tiny, stagnant worlds we leave behind—from the forgotten tire in the yard to the dish under the pot—proving that the most dangerous predators often breed in our own shadows.
Sources & References
- Reference 1WHOwho.intVisit source
- Reference 2CDCcdc.govVisit source
- Reference 3NCBIncbi.nlm.nih.govVisit source
- Reference 4THELANCETthelancet.comVisit source
- Reference 5ECDCecdc.europa.euVisit source
- Reference 6PAHOpaho.orgVisit source
- Reference 7PUBMEDpubmed.ncbi.nlm.nih.govVisit source
- Reference 8NEJMnejm.orgVisit source
- Reference 9RELIEFWEBreliefweb.intVisit source